CLINICAL_TRIALS
trial_result
· 2017-05-09
Clinical Trial Update: Efficacy and Safety of Ryanodex® (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS) [Phase 2]
Summary
Phase 2 trial assessing efficacy and safety of Ryanodex (EGL-4104) as adjuvant treatment for exertional heat stroke; study completed with posted results in 2017…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eagle Pharmaceuticals, Inc. | Conditions: Heat Stroke | Phase 2 | Status: COMPLETED | Results posted: 2017-05-09